Data from: Identification of candidate risk factor genes for human idelalisib toxicity using a collaborative cross approach

Merrie Mosedale, Yanwei Cai, J. Scott Eaddy, Robert Corty, Manisha Nautiyal, Paul B. Watkins & William Valdar
Idelalisib is a phosphatidylinositol 3-kinase inhibitor highly selective for the delta isoform that has shown good efficacy in treating chronic lymphocytic leukemia and follicular lymphoma. In clinical trials, however, idelalisib was associated with rare, but potentially serious liver and lung toxicities. In this study, we used the Collaborative Cross (CC) mouse population to identify genetic factors associated with the drug response that may inform risk management strategies for idelalisib in humans. Eight (8) male mice...
1 citation reported since publication in 2019.
157 views reported since publication in 2019.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?
13 downloads reported since publication in 2019.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?